Needham & Company LLC Reiterates “Buy” Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “buy” rating reiterated by equities research analysts at Needham & Company LLC in a report released on Thursday, Benzinga reports. They presently have a $7.00 target price on the stock. Needham & Company LLC’s price target would suggest a potential upside of 138.10% from the company’s current price.

TSHA has been the topic of a number of other research reports. Piper Sandler initiated coverage on Taysha Gene Therapies in a research note on Tuesday. They issued an “overweight” rating and a $9.00 target price on the stock. JMP Securities restated a “market outperform” rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Chardan Capital boosted their target price on Taysha Gene Therapies from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, March 21st. Canaccord Genuity Group restated a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, March 21st. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $6.88.

Taysha Gene Therapies Stock Down 8.7 %

NASDAQ:TSHA opened at $2.94 on Thursday. The firm has a market capitalization of $549.84 million, a price-to-earnings ratio of -4.39 and a beta of 0.29. Taysha Gene Therapies has a 1-year low of $0.50 and a 1-year high of $3.89. The company has a current ratio of 4.08, a quick ratio of 4.08 and a debt-to-equity ratio of 0.54. The business’s fifty day moving average price is $2.47 and its 200 day moving average price is $2.12.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Tuesday, March 19th. The company reported $0.35 earnings per share for the quarter. The business had revenue of $3.60 million for the quarter, compared to analyst estimates of $4.75 million. On average, sell-side analysts forecast that Taysha Gene Therapies will post -0.39 earnings per share for the current fiscal year.

Institutional Trading of Taysha Gene Therapies

Several large investors have recently made changes to their positions in the stock. FMR LLC lifted its position in shares of Taysha Gene Therapies by 2,035.0% during the 3rd quarter. FMR LLC now owns 24,527,801 shares of the company’s stock worth $77,508,000 after purchasing an additional 23,378,974 shares during the last quarter. RA Capital Management L.P. acquired a new position in shares of Taysha Gene Therapies during the 3rd quarter worth about $58,373,000. RTW Investments LP acquired a new position in shares of Taysha Gene Therapies during the 3rd quarter worth about $53,382,000. Vanguard Group Inc. lifted its position in shares of Taysha Gene Therapies by 16.3% during the 4th quarter. Vanguard Group Inc. now owns 6,195,567 shares of the company’s stock worth $10,966,000 after purchasing an additional 867,703 shares during the last quarter. Finally, Avoro Capital Advisors LLC lifted its position in shares of Taysha Gene Therapies by 11.0% during the 4th quarter. Avoro Capital Advisors LLC now owns 4,355,555 shares of the company’s stock worth $7,709,000 after purchasing an additional 430,555 shares during the last quarter. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.